Introduction
Severe congenital neutropenia (CN) is a hematologic disorder characterized by maturation arrest of granulopoiesis in bone marrow (BM) at the promyelocyte/myelocyte stage, absence of mature granulocytes in peripheral blood, and severe recurrent bacterial infections. 1,2 CN is a multigene syndrome caused by inherited mutations in several genes in subgroups of patients. Autosomal dominant mutations in the elastase 2 (ELA2) gene, encoding the neutrophil elastase (NE) protein, have been found in approximately 60% of patients with CN. 3 Novel autosomal recessive mutations in the HAX1 gene, encoding the mitochondrial protein HAX1, have been identified in approximately 10% to 15% of patients analyzed at the Hannover Medical School. 4 A causal connection between these gene mutations and defective granulopoiesis in CN is still unclear. Arrested promyelocytes from patients with CN showed impaired proliferation and differentiation in response to granulocyte colony-stimulating factor (G-CSF) in vitro. [5] [6] [7] Only daily administered pharmacologic doses of G-CSF (1-100 g/kg body weight per day) lead to sufficient numbers of granulocytes in the peripheral blood of patients with CN. BM morphology and response to G-CSF are similar in both subtypes of CN patient with mutations in the ELA2 gene or the HAX-1 gene. This finding suggests that similar factors or signaling pathways downstream of ELA2 and HAX1 mutations are involved in the pathologic process, causing the maturation arrest of myelopoiesis in CN.
We have identified lymphoid enhancer-binding factor 1 (LEF-1) as a decisive transcription factor in granulopoiesis controlling proliferation, proper lineage commitment, and granulocytic differentiation by C/EBP␣. 8 Myeloid progenitors from patients with CN showed a severe down-regulation or even a lack of LEF-1 and its target genes, including C/EBP␣, independent of the inheritance of ELA2 or HAX1 mutations. We postulated that the absence of LEF-1 plays a critical role in the defective maturation program of myeloid progenitors in CN. Moreover, it has been shown that LEF-1 and C/EBP␣ regulate the expression of ELA2 in BM cells by binding to the ELA2 promoter. 9 However, the specificity of this regulatory process for particular populations of BM cells, especially for myeloid progenitors, is not clear.
NE is a protease stored in primary granules of neutrophilic granulocytes that are formed during the promyelocytic phase of granulocyte differentiation. 10 NE is released after neutrophil activation and can cleave multiple substrates, including cytokines and chemokines (G-CSF and SDF1␣) [11] [12] [13] as well as cell-surface proteins (G-CSFR, VCAM, c-kit, and CXCR4). 12,14-17 G-CSF administration induces an increase in the level of NE in BM myeloid cells and the subsequent mobilization of BM stem cells to the peripheral blood. 16 By cleavage of the chemokine receptor CXCR4 and its ligand SDF-1␣, NE negatively regulates SDF1␣/ CXCR4 signaling, which plays a crucial role in the retention of hematopoietic cells within the BM and their mobilization to the peripheral blood. [14] [15] [16] [17] [18] [19] [20] [21] The degree of mobilization positively correlates with the down-regulation of the surface expression of CXCR4 by mobilized cells. The process of G-CSF-dependent stem cell mobilization is disturbed in patients with CN.
In the present study, we compared the expression levels of ELA2 and NE in myeloid cells and plasma from patients with CN carrying either ELA2 or HAX1 mutations with the expression of LEF1. We also investigated the LEF-1-dependent regulation of ELA2/NE in myeloid cells from patients with CN and in the myeloid cell line, U937. Our studies showed that down-regulation of ELA2/NE causes elevated surface expression of CXCR4 by BM cells from patients with CN.
Methods

Patients and controls
Twelve patients with CN harboring either ELA2 (n ϭ 8) or HAX1 (n ϭ 4) mutations; 4 patients with cyclic neutropenia (CyN), and 3 healthy volunteers participated in this study. All patients with neutropenia were treated long-term (Ͼ 1 year) with G-CSF in a dose between 2 and 7.5 g/kg per day at the time of study. None of the patients have developed acute myeloid leukemia or myelodysplastic syndrome so far. Three healthy volunteers received G-CSF in a dose of 5 g/kg per day for 2 days before BM was taken. BM samples were collected in association with the annual follow-up recommended by the Severe Chronic Neutropenia International Registry. Approval for this study was obtained from the Hannover Medical School's Institutional Review Board, and informed consent was obtained in accordance with the Declaration of Helsinki.
Purification and separation of CD34 ؉ and CD33 ؉ progenitor cells BM aspirates were obtained from the posterior iliac crest by standard techniques. BM mononuclear cells were isolated by Ficoll-Hypaque gradient centrifugation (Amersham Bioscience). For shRNA experiments, G-CSF-primed CD34 ϩ cells were harvested by leukapheresis from healthy volunteers. CD33 ϩ and CD34 ϩ cells were positively selected with the use of sequential immunomagnetic labeling and sorting according to the manufacturer's protocol (Miltenyi Biotec Inc). Cells were counted, and viability was assessed by trypan blue dye exclusion. Purity of sorted cells was greater than 96% as tested by FACS analysis and by hematoxylin/eosin staining of cytospin preparations.
Laser-assisted cell picking
Laser-assisted cell picking from BM slides was performed with the use of the PALM Laser-MicroBeam System that enables the contact-free isolation of single cells. The BM slides were fixed and stained with hematoxylin/ eosin. The microdissected cells (100 cells per sample) were catapulted into the lid of a 0.5-mL reaction tube with the use of the laser pressure catapulting technique of the instrument. RNA was isolated with TRIzol reagent according to the manufacturer's protocol (Invitrogen) with slight modifications: 10 ng/mL tRNA (Sigma-Aldrich) and 50 ng/mL linear polyacrylamide (LPA; Sigma-Aldrich) were added to the TRIzol reagent to increase the RNA yield. cDNA synthesis was performed with random hexamer priming and MuLV reverse transcriptase (Fermentas).
qRT-PCR
For quantitative real-time reverse transcription PCR (qRT-PCR), we isolated RNA with the use of the QIAGEN RNeasy Mini Kit with the manufacturer's protocol, amplified cDNA with random hexamer primer (Fermentas), and measured mRNA expression with the SYBR green qPCR kit (QIAGEN). Target gene mRNA expression was normalized to ␤-actin and was represented as arbitrary units (AUs). Primer sequences are available on request.
Western blot analysis
We used the following antibodies: goat polyclonal anti-ELA2 (Santa Cruz Biotechnology Inc), rabbit polyclonal anti-ELA2 (Calbiochem), mouse monoclonal anti-LEF-1 (REMB1; Calbiochem), mouse monoclonal anti-␤-actin (Santa Cruz Biotechnology Inc), and secondary anti-mouse or anti-rabbit HRP-conjugated antibody from Santa Cruz Biotechnology Inc. We obtained whole-cell lysates either through lysis of a defined number of cells in lysis buffer or through direct disruption in Laemmli loading buffer followed by brief sonication. We separated proteins by 10% SDS polyacrylamide gel electrophoresis and probed the blots either 1 hour at 24°C or overnight at 4°C.
Analysis of the NE protein by ELISA
The concentrations of NE in plasma and in culture supernatants were assayed in duplicate in appropriately diluted samples with an NE-specific enzyme-linked immunoabsorbent assay (ELISA) kit (Hycult Biotechnology). The detection limit of the assay was 0.4 ng/mL (NE).
FACS analysis of CXCR4 surface expression on BM CD34 ؉ cells
The following antibodies were used: primary unconjugated rat anti-CXCR4 (a gift of Prof R. Förster, Institute of Immunology, Hannover Medical School, Hannover, Germany), secondary APC-conjugated anti-rat antibody. Isotype control mAbs with irrelevant specificities were obtained from Immunotech. Expression of CXCR4 was measured with a FACScan flow cytometer (Becton Dickinson).
Chemotaxis assay
Chemotaxis assay was used to detect CXCR4/SDF1␣-dependent chemotactic activity of BM CD34 ϩ cells in vitro. CD34 ϩ cells from 4 patients with CN treated with G-CSF and 2 healthy volunteers treated with G-CSF were suspended at 5 ϫ 10 6 cells/mL of RPMI 1640 medium and 0.5% BSA. CD34 ϩ cell suspension (100 L) was placed into the insert of a Transwell chemotaxis chamber, and the bottom well was filled with 600 L RPMI/ 0.5% BSA (negative control) or the same medium supplemented with 10 ng/mL SDF1␣. Inserts were transferred to the lower chambers and incubated at 37°C and 6% CO 2 for 6 hours. When indicated, BM cells were preincubated with 100 g/mL purified human NE. After the incubation, 50 L of 70 mM EDTA solution was added into the lower chambers to release adherent cells from the lower surface of the membrane and from the bottom of the well. Plates were further incubated for 30 minutes at 4°C, inserts were removed, and the transmigrated cells were vigorously suspended and counted with a FACSCalibur for 1 minute at 60 L/min with gating on forward scatter and side scatter. Migration of CD34 ϩ cells from the insert to the bottom well was calculated as the percentage of total cells loaded into the upper chamber.
Transduction and G-CSF stimulation of CD34 ؉ cells from 2 patients with CN
LEF-1 cDNA synthesis and construction of LEF-1-GFP lentiviral vectors, anti-LEF-1 shRNA synthesis and construction of shRNA-RFP containing lentiviral vectors, as well as preparation of recombinant lentiviral supernatants and lentiviral transduction of the myeloid cell lines and primary CD34 ϩ cells, has been described previously. 8 For the G-CSF stimulation experiment, sorted GFP ϩ (for LEF-1 lv) or RFP ϩ (for anti-LEF-1 shRNA) CD34 ϩ cells were cultured for 4 days in 24-well tissue-culture plates (Costar; 2 ϫ 10 5 cells/well) in X-vivo medium supplemented with 1% heat-inactivated autologous human serum with or without the addition of 10 ng/mL rhG-CSF. For LEF-1 dose-dependent experiments, GFP ϩ cells were sorted by FACSCanto flow cytometer dependent on low, medium, or high intensity of GFP. Alternatively, transduced and sorted U937 cells were cultured in RPMI/10% FCS medium.
Determination of ELA2 mRNA stability
Serum-deprived THP1 and NB4 myeloid cell lines were treated with or without G-CSF (10 ng/mL) for 24 hours. Measurements of ELA2 mRNA stability were performed by inhibiting transcription with actinomycin D (5 g/mL; catalog no. A4262, Sigma-Aldrich) for the indicated time points. Amount of ELA2 mRNA was quantified with qRT-PCR.
Statistical analysis
Statistical analysis was performed with the SPSS Version 9.0 statistical package (SPSS Inc). To analyze differences in mean values between groups, a 2-sided unpaired Student t test was used.
Results
Abrogated levels of ELA2 mRNA in CD33 ؉ myeloid progenitors and of NE in plasma of patients with CN harboring either ELA2 or HAX1 mutations
To evaluate the ELA2 mRNA expression profile during granulocyte differentiation of hematopoietic cells, we performed laserassisted single-cell isolation of defined populations of hematopoietic cells in BM smears from patients with CN and healthy volunteers and measured ELA2 mRNA levels in defined cells. We found the highest ELA2 mRNA levels in promyelocytes from healthy volunteers but very low levels of ELA2 in these cells from patients with CN ( Figure 1A ). Analysis of ELA2 mRNA expression in CD33 ϩ myeloid progenitors showed G-CSF-dependent upregulation of ELA2 mRNA in healthy volunteers. By comparison, the CD33 ϩ cells from patients with CN showed markedly lower ELA2 mRNA levels that were not up-regulated by G-CSF ( Figure  1B ). In contrast, ELA2 mRNA expression in CD33 ϩ cells from patients with CyN was comparable with that of healthy volunteers ( Figure 1B ). Moreover, both groups of patients with CN, carrying ELA2 or HAX1 mutations, had comparable low levels of ELA2 mRNA ( Figure 1B ). Consistent with the low level of ELA2 mRNA, we found markedly diminished amounts of NE protein in the plasma from both groups of patients with CN, compared with G-CSF-treated healthy volunteers and patients with CyN ( Figure  1C ). Furthermore, neutrophils from patients with CN failed to release the NE protein after in vitro stimulation with G-CSF (data not shown).
To evaluate the effects of G-CSF on ELA2 mRNA stability, we inhibited mRNA synthesis in the THP1 and NB4 myeloid cell lines with the use of actinomycin D and compared the amount of remaining mRNA after 2, 4, and 8 hours in G-CSF-stimulated and unstimulated groups of cells. We observed that ELA2 mRNA declined only up to 74.1% in THP1 cells and only up to 84.7% in NB4 cells ( Figure 1D -E). We further showed that G-CSF treatment does not alter the ELA2 mRNA stability in both cell lines ( Figure 1D-E) .
Together, our results show that the levels of ELA2 mRNA and NE protein are dramatically down-regulated in patients with CN, irrespective of gene mutation status.
LEF-1 rescue of CD34 ؉ cells of patients with CN with ELA2 or HAX1 mutations results in elevated ELA2 mRNA and NE protein synthesis
Previously, we have shown that the LEF-1 transcription factor is crucial for neutrophil granulocytopoiesis. 8 We found that C/EBP␣ is a target gene of LEF-1 8 and that mRNA expression of both LEF-1 and C/EBP␣ is markedly reduced in patients with CN ( Figure 2A -B). 8 LEF-1 and C/EBP␣ regulate ELA2 by binding to the ELA2 gene promoter. 9 Because LEF-1 and ELA2 are expressed at maximum levels in promyelocytes, we hypothesized that the lack of ELA2 expression in CN may be because of the absence of LEF-1. To test this hypothesis, we transduced CD34 ϩ cells from 2 patients with CN with LEF-1-expressing lentiviral vector and measured ELA2 mRNA and NE protein expression. We found up-regulation of ELA2 mRNA and elevated synthesis of NE protein in LEF-1-rescued cells of patients with CN, which was even higher after in vitro stimulation of these cells with G-CSF ( Figure 2C-D) . LEF-1-dependent up-regulation of ELA2 mRNA expression occurs in a dose-dependent manner ( Figure 2E ). Moreover, previously we have shown that restoration of LEF-1 expression led to normalization of the in vitro granulocytic differentiation of hematopoietic progenitors from patients with CN. 8 The findings of the present study confirmed that ELA2/NE is involved in this process.
Hematopoietic progenitor cells of patients with CN showed elevated CXCR4 surface expression and enhanced CXCR4-dependent chemotaxis NE is elevated in the BM of healthy persons treated with G-CSF.
One of the known functions of NE is that it cleaves CXCR4 expressed on the surface of CD34 ϩ cells. 20 Because the synthesis of NE is markedly down-regulated in patients with CN, we measured as a functional readout the surface expression of CXCR4 in CD34 ϩ BM cells from patients with CN treated with G-CSF and compared the levels of expression with CD34 ϩ cells from healthy volunteers treated with G-CSF. As expected, CXCR4 surface expression was up-regulated in CD34 ϩ cells from patients with CN because of the lack of functional NE protein ( Figure 3A) . Next, we analyzed the functional activity of up-regulated CXCR4 receptors. We compared the ability of CD34 ϩ cells from patients with CN and healthy volunteers to migrate toward the CXCR4 ligand, SDF-1␣, by using an in vitro chemotaxis assay. We found that the percentage of migrated CD34 ϩ cells was markedly higher in the CN group, which is consistent with the up-regulated levels of CXCR4 and indicates that the CXCR4 receptors are functionally active ( Figure 3B ). Because preincubation with functionally active NE induces a marked reduction in the migratory ability of CD34 ϩ cells from patients with CN, which is consistent with the reduced expression of CXCR4 ( Figure 3C ), we conclude that this process is NE specific. On the basis of these findings, we conclude that the 
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LEF-1 controls the levels of ELA2 mRNA and synthesis of NE in the myeloid cell line U937 and in CD34 ؉ hematopoietic cells in a dose-dependent manner
We evaluated whether the effect of LEF-1 on ELA2 and NE is only specific for hematopoietic cells from patients with CN or whether it is a general mechanism in myelopoiesis. We transduced the myeloid cell line U937 with a lentiviral expression vector containing LEF-1 cDNA and GFP as a marker ( Figure 4A ). We found that overexpression of LEF-1 in the U937 cell line led to the marked up-regulation of ELA2 mRNA, which is consistent with the elevated levels of intracellular NE and NE secreted into the culture medium, compared with untransduced cells or cells transduced with the control lentiviral construct containing GFP but not LEF-1 cDNA (Figure 4B-D) . Again, LEF-1 activated ELA2 and NE in a dose-dependent manner (data not shown). Similar results were observed after transduction of CD34 ϩ hematopoietic cells with the LEF-1-GFP construct (Figure 4E-F; data not shown).
We also evaluated the expression of ELA2 and NE in hematopoietic cells deficient in LEF-1. We inhibited the expression of LEF-1 by transducing the myeloid cell line U937 with a lentiviral vector that expressed LEF-1-specific shRNA and RFP ( Figure 5A ). We used 2 different LEF-1-specific shRNAs and 1 nonspecific shRNA as a control. Analysis of U937 cells transduced with LEF-1-specific shRNAs showed marked down-regulation of ELA2 mRNA expression, NE protein secretion, and the intracellular NE protein level, compared with control cells (Figure 5B-D) . We found similar effects of LEF-1 inhibition in CD34 ϩ hematopoietic cells (Figure 5E-F) . Taken together, . NE protein secretion into culture supernatants (F) was assessed with the use of NE-specific ELISA; data represent means Ϯ SDs and are derived from 2 independent experiments each measured in triplicate (**P Ͻ .01 to G-CSF-stimulated ctrl shRNA samples).
these data suggest that a LEF-1-dependent mechanism is involved in the regulation of ELA2 and NE in hematopoietic cells.
Discussion
In the present study, we found diminished expression of ELA2 mRNA and NE protein in myeloid cells and plasma of patients with CN. Previous studies have reported reduced expression of ELA2 mRNA in the BM of patients with CN. 2, 3 However, the expression status of ELA2 in the myeloid subpopulation of BM cells was unknown, and the mechanism underlying the reduced expression of ELA2 in patients with CN was not clear. It was also unknown whether ELA2 mutations influenced the expression of ELA2 mRNA or the NE protein directly or both or whether the reduced expression of ELA2 in patients with CN was a result of abnormal ELA2 gene regulation by other factors. Autosomal dominant mutations in the ELA2 gene in patients with CN were initially described in 1999. 3 To date, more than 20 different mutations have been identified in the ELA2 gene. 22 In some cases, the same ELA2 mutations have been observed in the 2 different syndromes, CN and CyN. 3, 22, 23 ELA2 levels in patients with CyN, in which ELA2 is mutated in most patients, are comparable with the ELA2 levels in healthy persons. Therefore, other factors in addition to ELA2 mutations are responsible for the down-regulation of ELA2 transcription and NE expression in CN. This notion is supported by our data showing that ELA2 expression and NE protein levels in patients harboring HAX1 mutations are similarly abrogated. Moreover, several additional disputed observations suggest that the downstream effects of ELA2 mutations are not the only cause of CN: (1) there is no clear genotype-phenotype correlation, and more than 20 different ELA2 mutations confer widely disparate effects on NE enzymatic activity; (2) analysis of mutated recombinant NE proteins has shown no evident changes in protein stability or substrate specificity and no consistent effects on glycosylation, and proteolytic activity retained some mutants compared with the wild-type protein; and (3) gene targeting of ELA2 has failed to reproduce neutropenic phenotype in mice. Nevertheless, some studies have proposed that mutant ELA2 triggers accelerated apoptosis of granulocyte precursors. 24, 25 It was shown that ELA2 mutations lead to cytoplasmatic accumulation of the altered protein, disturbance of intracellular trafficking, activation of the unfolded protein response (UPR), and induction of endoplasmic reticulum (ER) stress-triggered apoptosis. 24, 25 However, it is not clear why ELA2 mutations do not cause UPR in patients with CyN and how HAX1 mutations would induce UPR and ER stress-induced apoptosis. Many unanswered questions remain about ER stress-induced apoptosis. Which molecules, associated with UPR (eg, ATF6, IRE1, PERK) are altered and which caspases are associated with the cell death. Continuous research is still necessary to outline the complexity of UPR. However, this was not the aim of this study. Previously, we found that the transcription factor LEF-1 plays a decisive role in granulopoiesis by direct activation of the granulocyte-specific transcription factor C/EBP␣. 8 Like ELA2 mRNA expression, LEF-1 is expressed at the highest levels in BM promyelocytes. 8 Both LEF-1 and C/EBP␣ activate the ELA2 gene by direct binding to the ELA2 promoter. 9, [26] [27] [28] Furthermore, myeloid progenitor cells of patients with CN showed a severe down-regulation or even a lack of LEF-1, C/EBP␣, and ELA2/NE expression in both groups, carrying either ELA2 or HAX1 mutations. 8 Wang et al 28 showed that C/EBP␣ and G-CSFR signals synergistically induce ELA2 expression. In addition, evidence is clear that G-CSF-dependent granulocytic differentiation is severely affected in patients with CN: (1) serum of these patients contains normal or increased levels of biologically active G-CSF, and G-CSF receptors (G-CSFRs) are expressed by CN myeloid cells at normal levels 29, 30 ; (2) patients with CN responded only to the regular subcutaneous administration of pharmacologic doses of recombinant human G-CSF (100-1000 times greater than physiologic levels) 1,2 ; and (3) in vitro growth of granulocyte colonies in CFU assays is defective with only a few neutrophil colonies formed, despite maximal stimulation with G-CSF. [5] [6] [7] In U937 cells we have shown that ELA2 expression and NE secretion directly depend on the intracellular levels of LEF-1, inhibition of LEF-1 led to reduced ELA2/NE production, and LEF-1 overexpression markedly enhanced the ELA2/NE levels. In hematopoietic progenitor cells from patients with CN, the in vitro reconstitution of LEF-1 expression by lentivirus-based transduction of LEF-1-GFP cDNA corrected the defective ELA2/NE levels and resulted in the differentiation of these progenitor cells into mature granulocytes. These results suggest that low ELA2/NE levels are involved in the complex multistep pathologic processes that ultimately lead to the maturation arrest of myeloid progenitors from patients with CN downstream of defective LEF-1. The importance of LEF-1 in the regulation of ELA2 is supported by the fact that the levels of ELA2 and NE are unaffected in patients with CyN, in whom the LEF-1 levels were comparable with healthy volunteers. 8 However, we cannot exclude the persistence of the other LEF-1-independent mechanisms of ELA2 regulation. As we have shown in Figure  1D and E, one of the possible mechanisms, namely enhancement of ELA2 mRNA stability by G-CSF treatment, is not involved in the control of ELA2 mRNA levels.
The existence of the LEF-1/C/EBP␣-independent mechanisms of the regulation of granulopoiesis in patients with CN is supported by the fact that treatment of these patients with G-CSF stimulates granulocytic differentiation even if LEF-1 and C/EBP␣ are significantly down-regulated. Patients with CN must receive daily pharmacologic doses of G-CSF 1,2 to be able to induce additional factors or signaling mechanisms that partially compensate for the deregulated "classical" signaling systems downstream of G-CSFR. Recently, we identified nicotinamide phosphoribosyl transferase (NAMPT), also known as pre-B-cell colony-enhancing factor, as an essential enzyme mediating G-CSF-triggered granulopoiesis in healthy persons and in persons with CN. 31 The enzyme NAMPT converts nicotinamide to nicotinamide mononucleotide, which is converted into nicotinamide adenine dinucleotide (NAD ϩ ) by nicotinamide mononucleotide adenylyltransferase in the mammalian biosynthetic pathway. 9 NAD ϩ regulates the transcription and function of sirtuins (SIRTs), which are lysine deacetylases for C/EBP␣ and C/EBP␤. 31 Intriguingly, in line with elevated NAMPT levels, amounts of NAD ϩ and SIRT1 protein in myeloid cells, as well as plasma NAD ϩ levels, were increased by G-CSF treatment of persons with CN. 31 Because in the myeloid cells of patients with CN C/EBP␣ is severely down-regulated, 8 it is not available for binding to SIRT1. However, we found that in contrast to C/EBP␣, normal or even elevated amounts of C/EBP␤ were expressed in these cells of persons with CN. C/EBP␣ and C/EBP␤ have different functions in granulopoiesis. C/EBP␣ is responsible for steady state granulopoiesis, whereas C/EBP␤ is crucial for cytokineinduced "emergency" granulopoiesis. 32 Therefore, we hypothesize that high NAMPT, NAD ϩ , and SIRT1 levels activate a C/EBP␤-dependent emergency pathway of neutrophil granulopoiesis in patients with CN, whereas the steady state regulation by LEF-1 and C/EBP␣ does not function. 8 
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BLOOD, 1 OCTOBER 2009 ⅐ VOLUME 114, NUMBER 14 For personal use only. on November 13, 2017. by guest www.bloodjournal.org From PU.1 is another extensively studied myeloid-specific transcription factor. 33, 34 The relative levels of PU.1 and C/EBP␣ in granulocytic-macrophage progenitors have been suggested to regulate monocyte versus neutrophil cell fate choice. Although these factors are known to positively regulate each other in early hematopoietic progenitors, they probably have opposite functions in myelopoiesis. The relative levels of PU.1 and C/EBP␣ in granulocytic-macrophage progenitors have been suggested to regulate monocyte versus neutrophil cell fate choice. 35 Thus, during granulocytic differentiation C/EBP␣ is up-regulated and PU.1 is repressed (but still expressed at the low levels), and monocytic differentiation occurs if PU.1 is activated and C/EBP␣ is inhibited, although the underlying molecular mechanism remains obscure. In patients with CN, the myelopoietic maturation program is sharply shifted toward monocytopoiesis (increased levels of monocytes from 2 to 4 times over normal and no granulocytes in peripheral blood), which may be because of the misbalanced C/EBP␣/PU.1 expression ratio in their myeloid cells. Indeed, in addition to severely abrogated C/EBP␣, PU.1 is slightly up-regulated in myeloid cells from patients with CN. 36 Rosenbauer et al 37 identified a key upstream regulatory element of PU.1 gene, which contained LEF-1/TCF binding sites. They have shown that LEF-1/TCFs function as transcriptional inhibitors of PU.1 gene expression. 37 On the basis of these findings, we conclude that in LEF-1-deficient myeloid cells from patients with CN a disturbed C/EBP␣/PU.1 ratio with a strong shift toward PU.1 may play a decisive role in the improper regulation of myelopoiesis with defective granulocytopoiesis and elevated monocytic differentiation. 36 This theory was supported by our data showing increased GM-CSF-dependent differentiation of LEF-1-deficient CD34 ϩ cells toward monocytes/ macrophages in vitro. 8 The aforementioned data suggest the involvement of LEF-1 in the complex regulatory network of the myeloid-specific signaling pathways, which are severely deregulated in patients with CN ( Figure 6 ). However, further experiments are needed to confirm and to understand the ultimate effects of the interaction between these transcription factors on the myeloid lineages decision in CN patients.
The ELA2 gene is specifically transcribed in promyelocytes in the BM, but the NE protein persists in cells through terminal differentiation into neutrophilic granulocytes. 10 NE is released after neutrophil activation and cleaves multiple substrates, including cytokines and chemokines (G-CSF and SDF1␣) [11] [12] [13] as well as cell-surface proteins (G-CSFR, VCAM, and c-kit). 12, [14] [15] [16] It was reported that NE cleaves CXCR4 expressed on the surface of CD34 ϩ cells. 20 Levesque et al 20 have shown that the administration of G-CSF leads to inactivation of the SDF1␣/CXCR4 chemotactic pathway due to proteolytic cleavage by NE, thereby facilitating the egress of CD34 ϩ cells from BM into the blood. The proteolytic cleavage of either SDF1␣ or CXCR4 by NE leads to complete inactivation of the SDF1␣/CXCR4 pathway. [17] [18] [19] [20] We therefore investigated whether expression of CXCR4 in patients with CN is normal or even elevated as a functional consequence of the missing NE activity. Indeed, we have shown that abolished synthesis of the NE protein in CN was associated with abnormally high CXCR4 expression by CD34 ϩ cells. Intriguingly, our attempts to mobilize CD34 ϩ cells in a patient with CN (as a backup treatment before allogenic BM transplantation) were unsuccessful, despite a temporary 10-fold increase in the daily administered G-CSF dose (K.W., unpublished data, December 2000). The unsuccessful mobilization of CD34 ϩ cells in the patient with CN may be due to the elevated expression of CXCR4 that results from the lack of NE production. On the basis of these data, CXCR4 antagonists could be used for stem cell mobilization in patients with CN alternatively to G-CSF. [38] [39] [40] The potential compensation of defective NE expression and missing protein function by other neutrophil proteases, such as proteinase 3, cathepsin G, or MMP9, is not possible because, in patients with CN, these proteases are down-regulated to the same degree as NE (Kawaguchi 41 and our data 42 ).
In summary, we have shown that the expression of ELA2 mRNA and the production of functional NE protein were markedly down-regulated in all patients with CN, independent of the presence of ELA2 or HAX1 mutations. We confirmed that the down-regulation of ELA2 mRNA expression and functional NE protein production was due to the absence of expression of the LEF-1 and C/EBP␣ transcription factors that directly activate ELA2 gene expression ( Figure 6 ).
